Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...237238239240241242243244245246247...401402»
  • ||||||||||  Clinical, Journal:  The analysis of osteosarcopenia as a risk factor for fractures, mortality, and falls. (Pubmed Central) -  Nov 6, 2021   
    This pooled analysis demonstrated that osteosarcopenia significantly increased the risk of fractures, falls, and mortality, thus highlighting its relevance in daily life. Therefore, we suggest that elderly persons should be aware of the risks associated with osteosarcopenia.
  • ||||||||||  Journal:  The role of diet quality and dietary patterns in predicting muscle mass and function in men over a 15-year period. (Pubmed Central) -  Nov 6, 2021   
    Therefore, we suggest that elderly persons should be aware of the risks associated with osteosarcopenia. A Traditional dietary pattern higher in vegetables, wholegrain cereals, and animal protein was associated with greater skeletal muscle mass, and an anti-inflammatory diet, also rich in vegetables, fruit, and wholegrain cereals, was associated with greater skeletal muscle mass and better muscle function over 15 years.
  • ||||||||||  Breyanzi (lisocabtagene maraleucel) / BMS, Yescarta (axicabtagene ciloleucel) / Gilead, Daiichi Sankyo
    Sarcopenia Is a Clinically Relevant and Independent Predictor of Health Outcomes after Chimeric Antigen Receptor T-Cell Therapy for Lymphoma (GWCC - Hall B5, Level 1) -  Nov 5, 2021 - Abstract #ASH2021ASH_4134;    
    Sarcopenia is an important and independent predictor of outcomes after CAR-T with potential downstream health-economic consequences, including increased burden of acute toxicities and prolonged length of hospitalization. Taken together, these data form the basis for real-time decision making prior to CAR-T (e.g. pre-habilitation, consideration of alternative treatments), or during/shortly after CAR-T (e.g.
  • ||||||||||  Niagen (nicotinamide riboside) / ChromaDex
    Trial completion:  CoNR: Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease (clinicaltrials.gov) -  Nov 5, 2021   
    P2,  N=25, Completed, 
    Taken together, these data form the basis for real-time decision making prior to CAR-T (e.g. pre-habilitation, consideration of alternative treatments), or during/shortly after CAR-T (e.g. Recruiting --> Completed
  • ||||||||||  Journal:  Managing malnutrition in the community during the COVID-19 pandemic. (Pubmed Central) -  Nov 5, 2021   
    In addition, public health infection prevention and control measures can inadvertently reduce access to food and increase social isolation, thus adversely affecting people's nutritional status. This article outlines practical interventions for preventing and managing malnutrition in the community, particularly where it is exacerbated by the social restrictions in place to contain the COVID-19 pandemic.
  • ||||||||||  Clinical, Observational data, Journal:  A cross-sectional study about the relationship between physical activity and sarcopenia in Taiwanese older adults. (Pubmed Central) -  Nov 5, 2021   
    Compared with those with low PA, moderate to high PA protected against the risk of sarcopenia with the odds ratio (OR) 0.46 (95% CI 0.27-0.79, p-value = 0.005). A significant protective effect of PA on sarcopenia was found among the older adults after adjusting for sex, institutionalization, age, BMI, albumin, hemoglobin, HDL-C levels, history of cardiovascular disease, education level and alcohol drinking.
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Clinical, Journal:  Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib. (Pubmed Central) -  Nov 4, 2021   
    Rehabilitation strategies aimed at combating myopenia in children is important. Significant and early skeletal muscle loss occurs during treatment with cabozantinib in a high proportion of patients and is associated with poor PFS.
  • ||||||||||  Review, Journal:  Effects of Blood Flow Restriction Exercise and Possible Applications in Type 2 Diabetes. (Pubmed Central) -  Nov 4, 2021   
    BFRT may therefore qualify as a valuable exercise alternative for individuals with type 2 diabetes (T2D), a disorder characterized by impaired glucose metabolism, musculoskeletal decline, and exacerbated progression of sarcopenia. This review covers the effects of BFRT in healthy populations and in persons with impaired physical fitness, the mechanisms of action of this novel training modality, and possible applications for individuals with T2D.
  • ||||||||||  Preclinical, Journal:  Age-Related Changes in the Matrisome of the Mouse Skeletal Muscle. (Pubmed Central) -  Nov 4, 2021   
    The current findings shed new light on the mutually cooperative interplay between cells and the extracellular environment in the aging SM. These data open the door for a better understanding of the mechanisms modulating myocellular behavior in aging (e.g., by altering mechano-sensing stimuli as well as signaling pathways) and their contribution to age-dependent muscle dysfunction.
  • ||||||||||  Review, Journal:  Nutritional therapy for hepatocellular carcinoma. (Pubmed Central) -  Nov 1, 2021   
    Nutritional therapy should be centered on providing enough energy and protein to manage the increased requirements of both cirrhosis and cancer. Supplementation with branched-chain amino acids is also recommended as it improves response to treatment, nutritional status and survival, and finally physical exercise must be encouraged and adapted to individual needs.
  • ||||||||||  Clinical, Journal:  Psoriasis Is Associated With Myosteatosis but Not Sarcopenia: A Case-Control Study. (Pubmed Central) -  Nov 1, 2021   
    Chronic plaque psoriasis is independently associated with myosteatosis but not sarcopenia. Since fat and muscle are considered endocrine organs and can drive the inflammatory process, further studies detailing the interaction between psoriasis, fat, and skeletal muscle are warranted.